Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.21M | 1.21M | 459.08K | 182.25K | 0.00 | 0.00 | Gross Profit |
1.21M | 1.21M | 459.08K | 182.25K | 0.00 | 0.00 | EBIT |
-116.47K | -2.13M | -8.55M | -4.03M | -2.44M | -3.29M | EBITDA |
-741.37K | -720.44K | 0.00 | 0.00 | 0.00 | 0.00 | Net Income Common Stockholders |
114.36K | -1.64M | -7.75M | -3.95M | -2.28M | -3.36M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
6.15M | 6.03M | 22.47M | 29.34M | 32.72M | 26.30M | Total Assets |
6.28M | 6.12M | 22.80M | 29.49M | 32.74M | 26.42M | Total Debt |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
-6.15M | -6.03M | -22.47M | -29.34M | -32.72M | -26.30M | Total Liabilities |
984.57K | 431.63K | 1.57M | 1.00M | 658.61K | 2.02M | Stockholders Equity |
5.30M | 5.69M | 21.23M | 28.48M | 32.08M | 24.40M |
Cash Flow | Free Cash Flow | ||||
-368.36K | -2.44M | -6.87M | -3.38M | -1.68M | -1.60M | Operating Cash Flow |
-368.36K | -2.44M | -6.87M | -3.38M | -1.68M | -1.60M | Investing Cash Flow |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
0.00 | -14.00M | 0.00 | 0.00 | 8.09M | 15.73M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $1.31B | 78.75 | 9.23% | ― | 10.79% | 5.20% | |
57 Neutral | AU$6.99M | 62.00 | 2.14% | ― | ― | ― | |
54 Neutral | AU$205.88M | ― | -37.20% | ― | ― | 32.02% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
45 Neutral | AU$21.39M | ― | -218.38% | ― | -14.30% | 29.69% | |
36 Underperform | $3.32M | ― | -119.28% | ― | ― | 64.10% |
Invex Therapeutics Ltd announced an expansion of its research collaboration with Tessara Therapeutics to further investigate the effects of Exenatide on Alzheimer’s Disease models, aiming to gain insights into its potential benefits on neural networks and gene expression. The company also reported prudent cash management with a closing balance of $5.7 million and highlighted a UK R&D tax incentive receipt, while continuing to explore additional asset opportunities.
Invex Therapeutics Ltd announced a change of its registered office address, now located at Level 5, 191 St Georges Terrace, Perth WA 6000. This relocation is part of compliance with ASX Listing Rule 3.14, and all other contact information remains unchanged. The announcement reflects ongoing organizational adjustments, which could have implications for its operational efficiencies and stakeholder communications.
Invex Therapeutics Ltd reported a significant decrease in other income and a substantial reduction in net loss for the half-year ending December 31, 2024, compared to the previous year. Despite the financial improvements, the company has not declared any dividends for the period, indicating a cautious approach in maintaining financial stability and potentially reinvesting in its operations.